Samarth Kulkarni - 04 Aug 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Signature
/s/ Michael Esposito, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
04 Aug 2021
Transactions value $
-$3,486,369
Form type
4
Filing time
06 Aug 2021, 20:00:29 UTC
Previous filing
22 Jun 2021
Next filing
03 Sep 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $18.9K +1.5K +0.8% $12.57 189K 04 Aug 2021 Direct
transaction CRSP Common Shares Sale -$188K -1.5K -0.79% $125.02 188K 04 Aug 2021 Direct F1, F2
transaction CRSP Common Stock Options Exercise $358K +28.5K +15.18% $12.57 216K 05 Aug 2021 Direct
transaction CRSP Common Stock Sale -$127K -1K -0.46% $126.67 215K 05 Aug 2021 Direct F1, F3
transaction CRSP Common Stock Sale -$601K -4.7K -2.18% $127.82 211K 05 Aug 2021 Direct F1, F4
transaction CRSP Common Stock Sale -$1.74M -13.5K -6.41% $128.85 197K 05 Aug 2021 Direct F1, F5
transaction CRSP Common Stock Sale -$885K -6.82K -3.46% $129.82 190K 05 Aug 2021 Direct F1, F6
transaction CRSP Common Stock Sale -$324K -2.48K -1.3% $130.51 188K 05 Aug 2021 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -1.5K -2.37% $0.00 61.8K 04 Aug 2021 Common Shares 30K $12.57 Direct F8
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -28.5K -46.09% $0.00 33.3K 05 Aug 2021 Common Stock 28.5K $12.57 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.33 to $127.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.37 to $128.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.37 to $129.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.38 to $130.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.38 to $130.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F8 This option was granted on July 15, 2016 with respect to 93,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.